They'll be heading to Phoenix with their families for a few days to meet players, participate in warmups, tour the clubhouse and throw out the first pitch at a spring training game.

In a mouse model of fibrodysplasia ossificans progressiva (FOP)-a genetic condition causing abnormal bone growth in soft tissues-DDR2 deficiency markedly reduced heterotopic ossification.

Fintel reports that on January 21, 2025, Cantor Fitzgerald downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) from Overweight to Neutral. Analyst Price Forecast Suggests 310.14% Upside As ...

TileDB, the database designed for discovery, today announced its availability through AWS Marketplace. AWS Marketplace is a digital catalog offering thousands of software solutions from independent ...

Zenus, a leader in behavioral analytics, and Captello, the innovators in trade show engagement and lead capture, joined forces to deliver groundbreaking results at this year's IAEE Expo! Expo! 2024 in ...

They'll be heading to Phoenix with their families for a few days to meet players, participate in warmups, tour the clubhouse ...

Health Canada has given the drug a green light – under the Sohonos brand – to treat fibrodysplasia ossificans progressiva (FOP), making it the first treatment for the ultra-rare genetic disorder.

The company has just claimed its first approval for the drug in Canada – under the Sohonos brand name – as a treatment for the ultra-rare genetic disorder fibrodysplasia ossificans progressiva ...

of andecaliximab in patients with fibrodysplasia ossificans progressiva (FOP). The dosing milestone for andecaliximab, āshibio’s lead product candidate, marks advancement of the company’s first ...